Embodiments of a method and supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals such as humans are disclosed. The supplement is in a tablet or capsule form and comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. A disclosed method of preventing and/or treating gastrointestinal distress comprises orally dosing an animal such as a human with the supplement at least once daily.

Embodiments of a method and supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals such as humans are disclosed. The supplement is in a tablet or capsule form and comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. A disclosed method of preventing and/or treating gastrointestinal distress comprises orally dosing an animal such as a human with the supplement at least once daily.

A nasal balm including, by weight, 10-50% of shea butter; 10-50% of coconut oil; 10-50% of Cera alba; 1-5% of grapefruit peel oil; 1-10% of Sclerocarya birrea seed oil; 1-10% of Moringa pterygosperma seed oil; and 1-10% of Simmondsia chinensis seed oil.

A nasal balm including, by weight, 10-50% of shea butter; 10-50% of coconut oil; 10-50% of Cera alba; 1-5% of grapefruit peel oil; 1-10% of Sclerocarya birrea seed oil; 1-10% of Moringa pterygosperma seed oil; and 1-10% of Simmondsia chinensis seed oil.

A nasal balm including, by weight, 10-50% of shea butter; 10-50% of coconut oil; 10-50% of Cera alba; 1-5% of grapefruit peel oil; 1-10% of Sclerocarya birrea seed oil; 1-10% of Moringa pterygosperma seed oil; and 1-10% of Simmondsia chinensis seed oil.

Disclosed are means, methods and compositions of matter useful for treatment of lung inflammation associated with viral and bacterial infections, as well as with systemic inflammation, through administration of umbilical cord blood derived plasma-based compositions. In one embodiment the invention teaches administration of umbilical cord blood plasma together with pterostilbene, and/or sulforaphane, and/or thymoquinone, and/or Epigallocatechin gallate (EGCG) and/or n-acetylcysteine in an aerosolized manner to patients suffering from COVID-19 associated pulmonary deficiencies. In another embodiment, umbilical cord blood plasma is administered with immune stimulatory agents in order to concurrently inhibit propagation of viral load in the lung while suppressing pulmonary deficiencies.

Disclosed are means, methods and compositions of matter useful for treatment of lung inflammation associated with viral and bacterial infections, as well as with systemic inflammation, through administration of umbilical cord blood derived plasma-based compositions. In one embodiment the invention teaches administration of umbilical cord blood plasma together with pterostilbene, and/or sulforaphane, and/or thymoquinone, and/or Epigallocatechin gallate (EGCG) and/or n-acetylcysteine in an aerosolized manner to patients suffering from COVID-19 associated pulmonary deficiencies. In another embodiment, umbilical cord blood plasma is administered with immune stimulatory agents in order to concurrently inhibit propagation of viral load in the lung while suppressing pulmonary deficiencies.

There is provided a skin-care balm comprising 15% to 45% (w/w) of two or more waxes, wherein a first wax has a melting point of 70° C. to 90° C. and a second wax has a melting point of 30° C. to 60° C., the balm further comprising 45% to 70% (w/w) of an emollient and a skin soothing agent. The skin-care balm can be applied to the skin in the perinasal area. There is also provided a combination product comprising a skin-care balm and a nasal spray product.

There is provided a skin-care balm comprising 15% to 45% (w/w) of two or more waxes, wherein a first wax has a melting point of 70° C. to 90° C. and a second wax has a melting point of 30° C. to 60° C., the balm further comprising 45% to 70% (w/w) of an emollient and a skin soothing agent. The skin-care balm can be applied to the skin in the perinasal area. There is also provided a combination product comprising a skin-care balm and a nasal spray product.

There is provided a skin-care balm comprising 15% to 45% (w/w) of two or more waxes, wherein a first wax has a melting point of 70° C. to 90° C. and a second wax has a melting point of 30° C. to 60° C., the balm further comprising 45% to 70% (w/w) of an emollient and a skin soothing agent. The skin-care balm can be applied to the skin in the perinasal area. There is also provided a combination product comprising a skin-care balm and a nasal spray product.